This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Portaccio, E Articles by Amato, M P Search for Related Content PubMed PubMed Citation Articles by Portaccio, E Articles by Amato, M P Social Bookmarking                         What's this?

Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria

Department of Neurology, University of Florence, 50134 Florence, Italy

V Zipoli

Department of Neurology, University of Florence, 50134 Florence, Italy

G Siracusa

Department of Neurology, University of Florence, 50134 Florence, Italy

S Sorbi

Department of Neurology, University of Florence, 50134 Florence, Italy

M P Amato

Department of Neurology, University of Florence, 50134 Florence, Italy, mariapia.amato{at}unifi.it

We assessed the proportion and potential predictors of response to interferon-beta (IFNß) therapy in relapsing-remitting (RR) multiple sclerosis (MS) patients, comparing different definitions of response: a) lower relapse rate during therapy compared to the year and the two years before therapy, b) reduction of relapse rate during therapy of at least 30% compared to the two years before therapy, c) no relapse during treatment, d) no progression on the Expanded Disability Status Scale (EDSS). Among 147 RR patients treated for at least one year, 33 received IFNß-1b subcutaneously (SC) (Betaferon), 59 IFNß-1a intramuscularly (Avonex) and 55 IFNß-1a SC (Rebif). Using definitions a), b) and d), 72%, 73% and 73% patients, respectively, were considered responders. Forty-four per cent of our patients were completely relapse free. In the logistic regression model, using definitions a) and b), a higher relapse rate in the two years preceding the therapy turned out to be a significant predictor of response. Considering definition c), lower baseline relapse rate was associated with a more favourable response.

Key Words: clinical criteria • interferon-beta therapy • multiple sclerosis • predictors of response

Multiple Sclerosis, Vol. 12, No. 3, 281-286 (2006)
DOI: 10.1191/135248506ms1278oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J Rio, J Castillo, A Rovira, M Tintore, J Sastre-Garriga, A Horga, C Nos, M Comabella, X Aymerich, and X Montalban Measures in the first year of therapy predict the response to interferon {beta} in MS Multiple Sclerosis, July 1, 2009; 15(7): 848 - 853. [Abstract] [PDF]